Device maker Iconovo and particle engineering specialist CrystecPharma have announced a non-exclusive collaboration agreement for development of dry powder inhalers. The companies say that they plan to develop engineered particles using CrystecPharma’s modified supercritical anti-solvent (mSAS) technology for delivery via one of Iconovo’s devices.
According to the companies, they “will promote each other’s technologies and expertise and will work jointly to provide end-to-end solutions for innovative pharmaceutical and biotechnology companies.” A pilot project using an Iconovo multi-dose device to deliver CrystecPharma’s lead candidate CR002 inhaled tolterodine for the treatment of urge incontinence is already underway.
Iconovo CEO Orest Lastow said, “This collaboration will help Iconovo to establish a more solid foundation in the innovative biotechnology space and a second revenue-generator on top of our current generic product offerings.”
CrystecPharma CEO Paul Thorning commented, “Working with Iconovo enables CrystecPharma to offer a more comprehensive inhaled product delivery solution to our customers, and a fast route to commercialization for novel inhaled products.”
Read the Iconovo and CrystecPharma press release.
